JP7436383B2 - 操作された調節性ｔ細胞 - Google Patents

操作された調節性ｔ細胞 Download PDF

Info

Publication number
JP7436383B2
JP7436383B2 JP2020556864A JP2020556864A JP7436383B2 JP 7436383 B2 JP7436383 B2 JP 7436383B2 JP 2020556864 A JP2020556864 A JP 2020556864A JP 2020556864 A JP2020556864 A JP 2020556864A JP 7436383 B2 JP7436383 B2 JP 7436383B2
Authority
JP
Japan
Prior art keywords
tcr
cells
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020556864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520831A5 (https=
JP2021520831A (ja
Inventor
ハンス シュタウス，
グラハム ピー． ライト，
ジェニー エル． マクガヴァン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806331.3A external-priority patent/GB201806331D0/en
Priority claimed from GBGB1806330.5A external-priority patent/GB201806330D0/en
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2021520831A publication Critical patent/JP2021520831A/ja
Publication of JP2021520831A5 publication Critical patent/JP2021520831A5/ja
Application granted granted Critical
Publication of JP7436383B2 publication Critical patent/JP7436383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
JP2020556864A 2018-04-18 2019-04-17 操作された調節性ｔ細胞 Active JP7436383B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806331.3A GB201806331D0 (en) 2018-04-18 2018-04-18 Method
GB1806331.3 2018-04-18
GBGB1806330.5A GB201806330D0 (en) 2018-04-18 2018-04-18 Engineered regulatory T cell
GB1806330.5 2018-04-18
PCT/GB2019/051097 WO2019202322A1 (en) 2018-04-18 2019-04-17 Engineered regulatory t cell

Publications (3)

Publication Number Publication Date
JP2021520831A JP2021520831A (ja) 2021-08-26
JP2021520831A5 JP2021520831A5 (https=) 2022-03-31
JP7436383B2 true JP7436383B2 (ja) 2024-02-21

Family

ID=66286535

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556864A Active JP7436383B2 (ja) 2018-04-18 2019-04-17 操作された調節性ｔ細胞
JP2020556883A Active JP7391038B2 (ja) 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020556883A Active JP7391038B2 (ja) 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Country Status (11)

Country Link
US (4) US12227756B2 (https=)
EP (2) EP3781673A1 (https=)
JP (3) JP7436383B2 (https=)
KR (1) KR20210003810A (https=)
CN (2) CN112004924A (https=)
AU (2) AU2019254824B2 (https=)
CA (2) CA3105303A1 (https=)
GB (3) GB2611707A (https=)
IL (1) IL278016B2 (https=)
SG (1) SG11202010154UA (https=)
WO (2) WO2019202322A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553379A (ja) * 2019-10-23 2022-12-22 ユーシーエル ビジネス リミテッド 操作された制御性ｔ細胞

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436383B2 (ja) 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞
EP3921427A1 (en) * 2019-02-05 2021-12-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant vectors suitable for the treatment of ipex syndrome
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
AU2021373326A1 (en) * 2020-11-09 2023-06-22 Quell Therapeutics Ltd Method for cryopreserving engineered tregs
US20220169687A1 (en) 2020-11-10 2022-06-02 Kyverna Therapeutics, Inc. Method for treating disease using foxp3+cd4+ t cells
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
AU2022349176A1 (en) * 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
US20230210900A1 (en) * 2022-01-04 2023-07-06 Kyverna Therapeutics, Inc. Methods for treating autoimmune diseases
EP4496883A1 (en) 2022-03-22 2025-01-29 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
CN119325506A (zh) * 2022-05-05 2025-01-17 圭尔医疗有限公司 维持调节性t细胞的抑制活性的方法
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183056A1 (en) 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
JP2018506287A (ja) 2015-02-16 2018-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1105479B1 (en) 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1967525B1 (en) 2001-05-08 2012-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
BRPI0610203A2 (pt) 2005-05-24 2010-06-01 Avestha Gengraine Tech Pvt Ltd processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
JP5626164B2 (ja) 2011-07-26 2014-11-19 日本精工株式会社 ステアリングコラム用支持装置
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2523058C2 (ru) 2012-06-29 2014-07-20 Общество с ограниченной ответственностью "Регенекс" Способ терапии ремиттирующего рассеянного склероза
WO2014145970A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Modulation of regulatory t cells via g-coupled protein receptor 43
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017062035A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
AU2017291262A1 (en) 2016-06-30 2019-01-03 F. Hoffmann-La Roche Ag Improved adoptive T-cell therapy
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
WO2018231759A1 (en) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
WO2018236909A1 (en) 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
WO2019079034A1 (en) 2017-10-17 2019-04-25 The General Hospital Corporation METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES
JP7436383B2 (ja) 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
GB201915384D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Vector
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183056A1 (en) 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
JP2018506287A (ja) 2015-02-16 2018-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Edinburgh Napier UNIVERSITY, [online], Riddell, V.，"Generating Ag-specific Human Regulatory T-cell by TCR Gene Transfer for the Treatment of Rheumatoid Arthritis"，2018年01月，Internet, [retrieved on 2023.02.13],，<URL: https://www.napier.ac.uk/-/media/worktribe/output-1532334/generating-ag-specific-human-regulatory-t-cell-by-tcr-gene-transfer-for-the-treatment-of.ashx>
GenPept, [online], Accession No: 3O6F_C, Chain C, T-cell Receptor Alpha Chain C Region, 2011.09.07 uploaded，Internet, [retrieved on 2023.02.13]，<URL: https://www.ncbi.nlm.nih.gov/protein/325053921?sat=16&satkey=10605105>
GenPept, [online], Accession No: 3O6F_D, Chain D, T-cell Receptor Beta-1 Chain C Region, 2011.09.07 uploaded，Internet, [retrieved on 2023.02.13]，<URL: https://www.ncbi.nlm.nih.gov/protein/325053922?sat=16&satkey=10605105>
Kim, Y. C. et al.，"Engineered myelin basic protein (MBP)-specific human T regulatory cells ameliorate myelin oligodendrocyte glycoprotein (MOG) peptide-induced Experimental Autoimmune Encephalomyelitis in vivo"，J. Immunol., [online]，2017年05月01日，Vol. 198 (1_Supplement): 219.15.，Internet, [retrieved on 2023.02.13]，<URL: https://journals.aai.org/jimmunol/article/198/1_Supplement/219.15/77323/Engineered-myelin-basic-protein-MBP-specific-human?searchresult=1>
MMDB, [online], 3O6F: Crystal Structure Of A Human Autoimmune Tcr Ms2-3c8 Bound To Mhc Class Ii Self-ligand Mbp/hla-dr4, 2011.09 uploaded，Internet, [retrieved on 2023.02.13]，<URL: https://www.ncbi.nlm.nih.gov/Structure/pdb/3O6F>
Muraro, P. A. et al.，"Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire"，J. Clin. Invest.，1997年，Vol. 100，pp. 339-349
WRIGHT, Graham P. et al.，"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis"，Proceedings of the National Academy of Sciences，2009年，Vol. 106，pp. 19078-19083
YIN, Y. et al.，"Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection"，The EMBO Journal，2011年，Vol. 30，pp. 1137-1148

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553379A (ja) * 2019-10-23 2022-12-22 ユーシーエル ビジネス リミテッド 操作された制御性ｔ細胞

Also Published As

Publication number Publication date
GB2611707A (en) 2023-04-12
KR20210003810A (ko) 2021-01-12
US20210145884A1 (en) 2021-05-20
US12227756B2 (en) 2025-02-18
AU2019254824B2 (en) 2025-04-24
US12077774B2 (en) 2024-09-03
GB202300872D0 (en) 2023-03-08
US20210079425A1 (en) 2021-03-18
IL278016A (en) 2020-11-30
IL278016B2 (en) 2025-03-01
GB2611498A (en) 2023-04-05
JP7839774B2 (ja) 2026-04-02
GB2587988B (en) 2023-05-31
SG11202010154UA (en) 2020-11-27
IL278016B1 (en) 2024-11-01
GB202018103D0 (en) 2020-12-30
CA3105303A1 (en) 2019-10-24
JP2024026127A (ja) 2024-02-28
GB2587988A (en) 2021-04-14
JP2021520834A (ja) 2021-08-26
JP2021520831A (ja) 2021-08-26
GB2611498B (en) 2023-07-19
US20240384301A1 (en) 2024-11-21
US20250154532A1 (en) 2025-05-15
CN112334571B (zh) 2024-06-25
CN112334571A (zh) 2021-02-05
WO2019202323A1 (en) 2019-10-24
CN112004924A (zh) 2020-11-27
AU2019254824A1 (en) 2020-11-26
EP3781672B1 (en) 2025-06-18
GB202300916D0 (en) 2023-03-08
AU2019256783A1 (en) 2020-10-22
EP3781673A1 (en) 2021-02-24
WO2019202322A1 (en) 2019-10-24
JP7391038B2 (ja) 2023-12-04
EP3781672A1 (en) 2021-02-24
CA3098128A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
JP7436383B2 (ja) 操作された調節性ｔ細胞
JP7789666B2 (ja) Ｈｌａ特異的なキメラ抗原受容体
CN114641564B (zh) 工程化的调节性t细胞
US20220363733A1 (en) Engineered regulatory t cell
JP2025515116A (ja) 制御性ｔ細胞の抑制活性を維持するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240208

R150 Certificate of patent or registration of utility model

Ref document number: 7436383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150